Need Help?

miRNA expression data from primary tumors, metastasis and matched normals.

MicroRNAs (miRs) have been recognized as promising biomarkers. It is unknown to what extent tumor-derived miRs are differentially expressed between primary colorectal cancers (pCRCs) and metastatic lesions, and to what extent the expression profiles of tumor tissue differ from the surrounding normal tissue. Next-generation sequencing (NGS) of 220 fresh-frozen samples, including paired primary and metastatic tumor tissue and non-tumorous tissue from 38 patients, revealed expression of 2245 known unique mature miRs and 515 novel candidate miRs. Unsupervised clustering of miR expression profiles of pCRC tissue with paired metastases did not separate the two entities, whereas unsupervised clustering of miR expression profiles of pCRC with normal colorectal mucosa demonstrated complete separation of the tumor samples from their paired normal mucosa. Two hundred and twenty-two miRs differentiated both pCRC and metastases from normal tissue samples (false discovery rate (FDR) <0.05). The highest expressed tumor-specific miRs were miR-21 and miR-92a, both previously described to be involved in CRC with potential as circulating biomarker for early detection. Only eight miRs, 0.5% of the analysed miR transcriptome, were differentially expressed between pCRC and the corresponding metastases (FDR <0.1), consisting of five known miRs (miR-320b, miR-320d, miR-3117, miR-1246 and miR-663b) and three novel candidate miRs (chr 1-2552-5p, chr 8-20656-5p and chr 10-25333-3p). These results indicate that previously unrecognized candidate miRs expressed in advanced CRC were identified using NGS. In addition, miR expression profiles of pCRC and metastatic lesions are highly comparable and may be of similar predictive value for prognosis or response to treatment in patients with advanced CRC.

Request Access

Data originating from patient samples

The Amsterdam UMC, tumor genome analysis core, allows access to published datasets upon written application and signature of a Data Access Agreement (DAA). In addition, applications to clinical datasets require approval by a Data Access Committee (DAC), who assess whether the proposed work is allowed given patient consent, as well as the scientific purpose. To aid this process we ask you to provide the information below. Requests will be prioritised according to novelty of the research question. Applications with insufficient detail on objectives, justification, and methods/planned analyses are unlikely to be accepted. 1.Reference number for the dataset 2.Full legal name and address of university/institution 3.Name(s) of the Principle Investigator who will use the data: 4.Name(s) and job title(s) of any other investigators who will use the data: 5.Please provide a minimum of one reference to a publication that can be found on PubMed and where the Principle Investigator is an author: 6.How will the data be stored and where will it be stored? 7.What is the proposed study title and what are the objectives and outcomes of the study in which the data will be used 8.Please provide a brief justification or rationale for the proposed study (max 250 words) 9.Please provide a brief description of planned data analyses (max 250 words): 10.Will the results arising from use of the data be used for the creation of products for sale or for any commercial purpose?

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001001127 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00000861838 fq.gz 553.7 MB
EGAF00000861839 fq.gz 446.9 MB
EGAF00000861840 fq.gz 219.8 MB
EGAF00000861841 fq.gz 489.3 MB
EGAF00000861842 fq.gz 394.4 MB
EGAF00000861843 fq.gz 360.7 MB
EGAF00000861844 fq.gz 378.4 MB
EGAF00000861845 fq.gz 375.9 MB
EGAF00000861846 fq.gz 443.5 MB
EGAF00000861847 fq.gz 351.4 MB
EGAF00000861848 fq.gz 383.7 MB
EGAF00000861849 fq.gz 398.2 MB
EGAF00000861850 fq.gz 398.8 MB
EGAF00000861851 fq.gz 803.5 MB
EGAF00000861852 fq.gz 388.3 MB
EGAF00000861853 fq.gz 399.1 MB
EGAF00000861854 fq.gz 392.3 MB
EGAF00000861855 fq.gz 442.7 MB
EGAF00000861856 fq.gz 293.7 MB
EGAF00000861857 fq.gz 395.8 MB
EGAF00000861858 fq.gz 490.5 MB
EGAF00000861859 fq.gz 817.8 MB
EGAF00000861860 fq.gz 692.9 MB
EGAF00000861861 fq.gz 342.7 MB
EGAF00000861862 fq.gz 642.8 MB
EGAF00000861863 fq.gz 265.6 MB
EGAF00000861864 fq.gz 384.8 MB
EGAF00000861865 fq.gz 336.1 MB
EGAF00000861866 fq.gz 373.8 MB
EGAF00000861867 fq.gz 430.0 MB
EGAF00000861868 fq.gz 850.0 MB
EGAF00000861869 fq.gz 453.9 MB
EGAF00000861870 fq.gz 589.5 MB
EGAF00000861871 fq.gz 397.0 MB
EGAF00000861872 fq.gz 408.2 MB
EGAF00000861873 fq.gz 375.4 MB
EGAF00000861874 fq.gz 878.7 MB
EGAF00000861875 fq.gz 322.6 MB
EGAF00000861876 fq.gz 368.8 MB
EGAF00000861877 fq.gz 417.1 MB
EGAF00000861878 fq.gz 499.9 MB
EGAF00000861879 fq.gz 319.7 MB
EGAF00000861880 fq.gz 404.5 MB
EGAF00000861881 fq.gz 452.1 MB
EGAF00000861882 fq.gz 428.2 MB
EGAF00000861883 fq.gz 438.5 MB
EGAF00000861884 fq.gz 443.1 MB
EGAF00000861885 fq.gz 420.8 MB
EGAF00000861886 fq.gz 364.0 MB
EGAF00000861887 fq.gz 544.1 MB
EGAF00000861888 fq.gz 298.0 MB
EGAF00000861889 fq.gz 496.0 MB
EGAF00000861890 fq.gz 391.8 MB
EGAF00000861891 fq.gz 455.5 MB
EGAF00000861892 fq.gz 1.3 GB
EGAF00000861893 fq.gz 403.8 MB
EGAF00000861894 fq.gz 437.1 MB
EGAF00000861895 fq.gz 412.5 MB
EGAF00000861896 fq.gz 420.9 MB
EGAF00000861897 fq.gz 379.7 MB
EGAF00000861898 fq.gz 390.9 MB
EGAF00000861899 fq.gz 438.6 MB
EGAF00000861900 fq.gz 444.6 MB
EGAF00000861901 fq.gz 451.1 MB
EGAF00000861902 fq.gz 392.3 MB
EGAF00000861903 fq.gz 425.8 MB
EGAF00000861904 fq.gz 422.8 MB
EGAF00000861905 fq.gz 379.0 MB
EGAF00000861906 fq.gz 418.4 MB
EGAF00000861907 fq.gz 417.5 MB
EGAF00000861908 fq.gz 395.5 MB
EGAF00000861909 fq.gz 433.6 MB
EGAF00000861910 fq.gz 428.8 MB
EGAF00000861911 fq.gz 465.7 MB
EGAF00000861912 fq.gz 437.9 MB
EGAF00000861913 fq.gz 441.8 MB
EGAF00000861914 fq.gz 435.3 MB
EGAF00000861915 fq.gz 404.4 MB
EGAF00000861916 fq.gz 379.4 MB
EGAF00000861917 fq.gz 369.2 MB
EGAF00000861918 fq.gz 376.2 MB
EGAF00000861919 fq.gz 411.3 MB
EGAF00000861920 fq.gz 370.1 MB
EGAF00000861921 fq.gz 363.2 MB
EGAF00000861922 fq.gz 390.5 MB
EGAF00000861923 fq.gz 368.1 MB
EGAF00000861924 fq.gz 400.8 MB
EGAF00000861925 fq.gz 481.0 MB
EGAF00000861926 fq.gz 493.4 MB
EGAF00000861927 fq.gz 483.2 MB
EGAF00000861928 fq.gz 393.8 MB
EGAF00000861929 fq.gz 189.7 MB
EGAF00000861930 fq.gz 337.4 MB
EGAF00000861931 fq.gz 429.3 MB
EGAF00000861932 fq.gz 468.2 MB
EGAF00000861933 fq.gz 411.0 MB
EGAF00000861934 fq.gz 369.6 MB
EGAF00000861935 fq.gz 381.0 MB
EGAF00000861936 fq.gz 498.2 MB
EGAF00000861937 fq.gz 414.5 MB
EGAF00000861938 fq.gz 451.3 MB
EGAF00000861939 fq.gz 464.1 MB
EGAF00000861940 fq.gz 388.5 MB
EGAF00000861941 fq.gz 362.3 MB
EGAF00000861942 fq.gz 385.3 MB
EGAF00000861943 fq.gz 281.6 MB
EGAF00000861944 fq.gz 279.4 MB
EGAF00000861945 fq.gz 455.6 MB
EGAF00000861946 fq.gz 462.7 MB
EGAF00000861947 fq.gz 314.7 MB
EGAF00000861948 fq.gz 266.4 MB
EGAF00000861949 fq.gz 653.3 MB
EGAF00000861950 fq.gz 432.4 MB
EGAF00000861951 fq.gz 362.5 MB
EGAF00000861952 fq.gz 366.2 MB
EGAF00000861953 fq.gz 394.7 MB
EGAF00000861954 fq.gz 294.5 MB
EGAF00000861955 fq.gz 180.9 MB
EGAF00000861956 fq.gz 203.4 MB
EGAF00000861957 fq.gz 368.7 MB
EGAF00000861958 fq.gz 494.3 MB
EGAF00000861959 fq.gz 359.7 MB
EGAF00000861960 fq.gz 361.4 MB
EGAF00000861961 fq.gz 353.2 MB
EGAF00000902789 fq.gz 387.4 MB
125 Files (53.2 GB)